Precision BioSearch was delighted to partner with Myricx Bio, a biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), to secure the appointment of Dr Francesca Zammarchi as Chief Scientific Officer.

Francesca joins from ADC Therapeutics SA (NYSE: ADCT) where she served as Head of Preclinical Pharmacology. During her 10 years at ADC Therapeutics, she worked as a cancer biologist actively involved in the discovery and evaluation of new projects for the company’s portfolio, with responsibility for preclinical pharmacology studies, and progressed multiple ADCs with novel payloads through IND to BLA. Dr Zammarchi gained her Ph.D. in experimental and molecular oncology and her B.Sc. in molecular biology from the University of Pisa, Italy.

Commenting on the partnership with Precision BioSearch, Myricx Bio CEO Dr Robin Carr said, “It has been a pleasure to work with Precision BioSearch on the appointment of our CSO. They surpassed expectations, delivering a fantastic service from start to finish. We are delighted to have Francesca on board and would highly recommend Precision BioSearch to other therapeutics companies for C-suite executive search.”

Welcoming Francesca to the company, Dr Robin Carr said: “As we advance our unique ADC pipeline against important cancer targets, Francesca’s impressive background in ADC discovery and development provides an ideal skillset to lead our programmes as CSO. We believe our first-in-class selective cytotoxic payloads based on potent inhibitors of N-myristoyltransferase (NMT) will provide important advantages in the development of differentiated ADC therapeutics.”

About Myricx Bio: Based in Kings Cross, London, Myricx Bio is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Myricx Bio is the trading name of Myricx Pharma Limited.

For more information, visit: myricxbio.com